LarmorBio Announces New Data Presentation at European Atherosclerosis Society Congress in May Linking Oxidative Stress with Cardiovascular Risk
BOSTON MA, UNITED STATES, February 6, 2025 -- Currently in the United States nearly half of heart attacks and strokes occur in patients that are not deemed high-risk by traditional risk factors such as high blood pressure, high cholesterol, and diabetes. Additionally, half of adults ages 45 to 84 have atherosclerosis but are not aware of it. LarmorBio in partnership researchers at Tan Tock Seng hospital in Singapore have engaged in a large-scale study to evaluate whether a new biomarker, oxidative stress, can provide early indication of cardiovascular risk in patients who may not display traditional risk factors. The study is evaluating 1,500 high risk cardiovascular patients and comparing oxidative stress levels with disease outcomes. The study will use the company’s pioneering microscale magnetic resonance system which directly measures oxidative stress in blood samples using proprietary technology. The test can be conducted at low cost in less than five minutes by an untrained user.
The company is pleased to announce that Dr. Rinkoo Dalan from Tan Tock Seng Hospital will present initial findings from the study linking blood oxidative stress with vascular function at the 93rd European Atherosclerosis Society (EAS) Congress in Glasgow, UK from May 4-7, 2025. The data being presented is an interim analysis linking oxidative stress with diabetes risk and measurements of vascular function. Previous studies have shown that LarmorBio’s oxidative stress measure outperforms and provides independent value relative to gold standard measures such as fasting blood glucose and F2 isoprostane in predicting which patients have metabolic disease. However, this will be the first study demonstrating the ability of LarmorBio’s system to link oxidative stress with vascular function using its proprietary blood oxidative stress measurement.
“We are exceptionally excited to present this groundbreaking initial research around the role oxidative stress plays in cardiovascular risk in conjunction with our partners at Tan Tock Seng Hospital,” said Rodolfo Rohr, CEO at LarmorBio. “We believe oxidative stress has the potential to be a critical biomarker in chronic disease care including cardiometabolic disease by enabling testing for hidden damage occurring to tissue and organs in the body that previously was not available using traditional laboratory testing.”
About LarmorBio:
LarmorBio is a pioneering life science research and clinical diagnostic company that has developed a groundbreaking new microscale magnetic resonance technology for measuring critical biological data in blood and cell samples. The primary application of the technology to date is measuring oxidative stress levels in blood which plays a critical role in chronic disease progression. Prior to LarmorBio’s platform, no technology could directly measure oxidative stress and LarmorBio’s system can be performed in under five minutes at low cost by an untrained user. The company currently has deployed the system globally in partnership with major research hospitals and leading healthcare companies and has 12 peer-reviewed publications supporting the system’s clinical value.